Safety and Efficacy of SC101 Via Perirenal Fat Injection for Resistant Hypertension in Patients With Moderate to Severe Chronic Kidney Disease

This is a single-center, open-label, exploratory clinical study designed to evaluate the safety and efficacy of a single-session injection of SC101, a small interfering RNA (siRNA) agent, into the perirenal fat. This study plans to enroll 3 participants, aged 18 to 65 years, who have a clinical diagnosis of resistant hypertension and moderate to severe chronic kidney disease (CKD).

NCT Number	NCT07483372
Lead Sponsor	The First Affiliated Hospital with Nanjing Medical University Collaborators: Suzhou Municipal Hospital
Conditions	Resistant Arterial Hypertension, Chronic Kidney Disease (Stage 3-4)
Enrollment	3 participants
Start Date	2026-03-27
Primary Completion	2027-12-31 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-04-01